// App-Quantinova.ai

P277 : Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Bruce Kirkham

  • Proton Rahman

  • Philip Helliwell

  • Alice B Gottlieb

  • Wolf-Henning Boehncke

  • Xie L Xu

  • Patricia C Gorecki

  • Chenglong Han

Medical Centers

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Faculty of Medicine, Memorial University of Newfoundland, St. Johns, NF, Canada

  • School of Dentistry, University of Leeds, Leeds, UNITED KINGDOM

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Departement de Medecine, Geneva University Hospitals, Geneva, SWITZERLAND

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

Locations

  • United States

  • United Kingdom

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

  • guselkumab (IV)

  • Grace

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved